Table 2.
Total | Broad-spectrum antimicrobial group | Narrow-spectrum antimicrobial group | p value | |
---|---|---|---|---|
n = 254 | n = 159 | n = 95 | ||
Age | 72 (59–80.25) | 73 (62–80) | 72 (53–82) | 0.401 |
Sex | 0.698 | |||
Male | 143 (56.3%) | 88 (55.3%) | 55 (57.9%) | |
Female | 111 (43.7%) | 71 (44.7%) | 40 (42.1%) | |
Severity on ICU admission | ||||
APACHE II on ICU admission | 20 (15–26) | 21 (17–27) | 17 (13–26) | 0.002 |
SAPS II on ICU admission | 43 (29–57) | 48 (34–61) | 37 (22–50) | < 0.001 |
Total SOFA score on ICU admission | 7 (5–10) | 8 (5–11) | 5 (4–9) | < 0.001 |
Admission category | ||||
Medical | 175 (68.9%) | 109 (68.6%) | 66 (69.5%) | > 0.999 |
Surgical | 74 (29.1%) | 47 (29.6%) | 27 (28.4%) | 0.887 |
Trauma | 5 (2.0%) | 3 (1.9%) | 2 (2.1%) | > 0.999 |
Admission diagnosisa | ||||
Respiratory | 80 (31.5%) | 46 (28.9%) | 34 (35.8%) | 0.267 |
Digestive | 68 (26.8%) | 53 (33.3%) | 15 (15.8%) | 0.002 |
Cardiovascular | 62 (24.4%) | 36 (22.6%) | 26 (27.4%) | 0.451 |
Neurological | 36 (14.2%) | 17 (10.7%) | 19 (20.0%) | 0.043 |
Renal genitourinary | 30 (11.8%) | 17 (10.7%) | 13 (13.7%) | 0.548 |
Trauma skin | 21 (8.3%) | 12 (7.5%) | 9 (9.5%) | 0.641 |
Other | 26 (10.2%) | 16 (10.1%) | 10 (10.5%) | > 0.999 |
Comorbidities (N = 241) | ||||
Cardiovascular | 58 (24.1%) | 38 (25.0%) | 20 (22.5%) | 0.755 |
Diabetes mellitus | 54 (22.4%) | 35 (23.0%) | 19 (21.3%) | 0.873 |
Solid tumor | 40 (16.6%) | 28 (18.4%) | 12 (13.5%) | 0.372 |
Renal failure | 31 (12.9%) | 22 (14.5%) | 9 (10.1%) | 0.426 |
Cerebrovascular | 31 (12.9%) | 24 (15.8%) | 7 (7.9%) | 0.109 |
Pulmonary | 26 (10.8%) | 18 (11.8%) | 8 (9.0%) | 0.528 |
Other | 18 (7.5%) | 15 (9.9%) | 3 (3.4%) | 0.077 |
Results are shown as n (%) or median (IQR) where applicable
ICU intensive care unit, APACHE Acute Physiology and Chronic Health Evaluation, SAPS Simplified Acute Physiology Score, SOFA Sequential Organ Failure Assessment
aPatients could have multiple admission diagnoses